Even at this maximum, the metabolic impact falls below what tirzepatide 12.5 mg or 15 mg delivers
Real-world data from a Truveta study of over 18,000 patients found that tirzepatide users achieved greater weight loss at 12 months compared to semaglutide users, consistent with the SURMOUNT-5 findings [4]
Semaglutide, a GLP-1 receptor agonist, is broadly utilized in the treatment of type 2 diabetes & obesity, attaining strong traction in Sweden owing to the rising popularity of metabolic disorders & increasing health consciousness
Any changes in urination patterns whilst taking Ozempic are typically related to improved glycaemic control, dietary modifications, or unrelated conditions
This imbalance may lead to disruptions in glucose and lipid homeostasis, contributing to a range of metabolic diseases, including obesity